Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IBI110 |
Trade Name | |
Synonyms | IBI 110|IBI-110|negalstobart |
Drug Descriptions |
IBI110 is a monoclonal antibody that targets LAG3 on tumor infiltrating lymphocytes, and prevents the interaction between LAG3 and MHC II molecules expressed on antigen-presenting cells and tumor cells, potentially leading to increased cytotoxic T lymphocyte-mediated antitumor immune response and inhibition of tumor growth (NCI Drug Dictionary). |
DrugClasses | LAG3 Antibody 18 |
CAS Registry Number | 2360418-68-2 |
NCIT ID | C168603 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IBI110 | IBI110 | 0 | 0 |
IBI110 + Sintilimab | IBI110 Sintilimab | 0 | 1 |